# Neon Therapeutics

Source: https://onco.cc/companies/neon-therapeutics/  
OnCo record `neon-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Neon Therapeutics worked on cancer treatments that point the immune system at neoantigens, the changed proteins found only on a person's cancer cells. BioNTech bought it in 2020 and it became BioNTech's US base.

## Summary

Neon Therapeutics was an immuno-oncology company developing neoantigen-targeted therapies that direct the immune system towards neoantigens (Third Rock Ventures). BioNTech closed its all-stock acquisition of Neon (Nasdaq: NTGN) on 6 May 2020, after announcing the agreement on 16 January 2020. The Cambridge, Massachusetts subsidiary was to operate as BioNTech US Inc. and serve as BioNTech's US headquarters.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Neon Therapeutics, Inc.; BioNTech US Inc.
- HQ: Cambridge, MA
- Type: biotech

## Notes

- Named product candidates are not stated in the sources read; none recorded.
- Founding year not stated (2015 is Third Rock's year of investment).
- No ClinicalTrials.gov studies matched the sponsor name 'Neon Therapeutics'.

## Sources

- BioNTech completes acquisition (Neon 8-K exhibit, 6 May 2020): https://www.sec.gov/Archives/edgar/data/1694187/000169418720000050/ntgn-20200506xex991.htm
- Third Rock Ventures portfolio entry: https://www.thirdrockventures.com/portfolio/neon

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- companies: [BioNTech](https://onco.cc/companies/biontech/), [Third Rock Ventures](https://onco.cc/companies/third-rock-ventures/)

---
JSON: https://onco.cc/api/v1/entities/neon-therapeutics.json